Moderna shares plunge 25% as Merck confirms leaked Phase 3 data: cancer vaccine cuts melanoma recurrence risk by 42%

Moderna (MRNA) is trading 25% lower after Merck and Moderna reported Phase 3 results for intismeran autogene, the personalized melanoma vaccine used with Keytruda, confirming the leaked data: the combination cut melanoma recurrence or death risk by 42% versus Keytruda alone, with a 58% reduction in another measure and safety consistent with prior studies. Merck shares fell 3.1%.

Detected & updated continuously · Source: Nebula